Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 4/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.54 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.54 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.54 |
| ▸ | LDHA | P00338 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | FBP1 | P09467 | 1/20 | 0.54 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.54 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294351 | 0.88 | ADORA1 (0.58) | P2RY1ADORA1SMN1; SMN2P2RY2SRC | |
| SCHEMBL2297087 | 0.81 | P2RY1 (0.59) | P2RY1ADORA1SMN1; SMN2P2RY2SRC | |
| SCHEMBL6569310 | 0.79 | ADORA1 (0.73) | P2RY1ADORA1SMN1; SMN2P2RY2SRC | |
| SCHEMBL939593 | 0.78 | ADORA1 (0.71) | P2RY1ADORA1SMN1; SMN2P2RY2SRC | |
| SCHEMBL8708990 | 0.78 | ADORA1 (0.71) | P2RY1ADORA1SMN1; SMN2P2RY2SRC | |
| SCHEMBL939559 | 0.76 | ADORA2A (0.80) | ADORA1ADORA2AADORA2B | |
| SCHEMBL939554 | 0.76 | ADORA2A (0.80) | ADORA1ADORA2AADORA2B | |
| SCHEMBL939556 | 0.76 | ADORA2A (0.80) | ADORA1ADORA2AADORA2B | |
| SCHEMBL5327610 | 0.76 | P2RY1 (0.68) | P2RY1ADORA1SMN1; SMN2P2RY2SRC | |
| SCHEMBL926920 | 0.76 | P2RY1 (0.68) | P2RY1ADORA1SMN1; SMN2P2RY2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189255-A1 | DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION | PURDUE RESEARCH FOUNDATION | 2011-08-04 | — | — | US | claimed |
| US-20100272711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | THOMAS JEFFERSON UNIVERSITY (US) | 2010-10-28 | — | — | US | claimed |
| WO-2009076580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | THOMAS JEFFERSON UNIVERSITY (US) | 2009-06-18 | — | — | WO | claimed |
| EP-1014995-A4 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | ADERIS PHARMACEUTICALS INC (US) | 2005-02-16 | — | — | EP | claimed |
| US-6372723-B1 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS, INC. | 2002-04-16 | — | — | US | claimed |
| JP-2002505687-A | — | — | 2002-02-19 | — | — | JP | claimed |
| US-6339072-B2 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS INC. | 2002-01-15 | — | — | US | claimed |
| US-20010009907-A1 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS, INC. | 2001-07-26 | — | — | US | claimed |
| EP-1014995-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | Discovery Therapeutics, Inc. (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1998057651-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | DISCOVERY THERAPEUTICS, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| US-9414901-B2 | Drug-eluting stents for adenosine receptor modulation | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-08-16 | — | — | US | disclosed |
| US-20110189255-A1 | DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION | PURDUE RESEARCH FOUNDATION | 2011-08-04 | — | — | US | disclosed |
| US-20100272711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | THOMAS JEFFERSON UNIVERSITY (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2009076580-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | THOMAS JEFFERSON UNIVERSITY (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2007134271-A2 | METHOD AND APPARATUS FOR REDUCING INJURY FROM ACUTE MYOCARDIAL INFARCTION | INNOVATIONAL HOLDINGS LLC (US) | 2007-11-22 | — | — | WO | disclosed |
| US-6372723-B1 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS, INC. | 2002-04-16 | — | — | US | disclosed |
| US-6339072-B2 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS INC. | 2002-01-15 | — | — | US | disclosed |
| US-20010009907-A1 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS, INC. | 2001-07-26 | — | — | US | disclosed |
| EP-1014995-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | Discovery Therapeutics, Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1998057651-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | DISCOVERY THERAPEUTICS, INC. (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272711-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | ADORA2A, ADORA1, ADORA2B | P2RY1 26/4885ADORA1 2/4885SMN1; SMN2 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.